A company insider recently sold 4,504 shares of Arcutis Biotherapeutics Inc [ARQT]. Should You Sale?

Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Arcutis Biotherapeutics Inc shares valued at $90,263 were sold by Edwards Larry Todd on Oct 02 ’25. At $20.04 per share, Edwards Larry Todd sold 4,504 shares. The insider’s holdings dropped to 178,897 shares worth approximately $3.87 million following the completion of this transaction.

Also, Watanabe Todd sold 24,261 shares, netting a total of over 469,074 in proceeds. Following the sale of shares at $19.33 each, the insider now holds 867,179 shares.

Before that, Watanabe Todd had sold 20,739 shares from its account. In a trade valued at $415,574, the insider traded Arcutis Biotherapeutics Inc shares for $20.04 each. Upon closing the transaction, the insider’s holdings decreased to 20,739 shares, worth approximately $18.31 million.

As published in their initiating research note from Goldman on July 25, 2025, Arcutis Biotherapeutics Inc [ARQT] has been a Neutral and the price target has been revised to $18. Analysts at H.C. Wainwright started covering the stock with ‘”a Buy”‘ outlook in a report released in late December. As of August 28, 2024, Jefferies has initiated its “Buy” rating for ARQT. Earlier on January 03, 2024, Mizuho upgraded its rating. Their new recommendation was “a Buy” for ARQT stock which previously was a “a Neutral”.

Analyzing ARQT Stock Performance

On last trading session, Arcutis Biotherapeutics Inc [NASDAQ: ARQT] rose 5.87% to $21.63. The stock’s lowest price that day was $20.5, but it reached a high of $21.7 in the same session. During the last five days, there has been a surge of approximately 1.84%. Over the course of the year, Arcutis Biotherapeutics Inc shares have jumped approximately 120.94%.

Is Arcutis Biotherapeutics Inc subject to short interest?

Stocks of Arcutis Biotherapeutics Inc saw a sharp steep in short interest on 2025-09-30 dropping by -2.57 million shares to 14.45 million. Data from Yahoo Finance shows that the short interest on 2025-08-29 was 17.02 million shares. A decline of -17.75% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 7.82 of the overall float, the days-to-cover ratio (short ratio) decline to 7.82.

Which companies own the most shares of Arcutis Biotherapeutics Inc (ARQT)?

In terms of Arcutis Biotherapeutics Inc share price expectations, FactSet research, analysts set an average price target of 19 in the next 12 months, down nearly -7.0% from the previous closing price of $20.43. Analysts anticipate Arcutis Biotherapeutics Inc stock to reach 51 by 2025, with the lowest price target being 18. In spite of this, 3 analysts ranked Arcutis Biotherapeutics Inc stock as Buy at the end of 2025. On October 26, 2023, Mizuho assigned a price target of “a Neutral” to the stock and downgraded coverage with a $4.

Most Popular

Knox Daily
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.